Muhammad Azrul bin Abdul Hamid - 13 Aug 2026 Form 4 Insider Report for BioNexus Gene Lab Corp (BGLC)

Reporting relationship: Director
Issuer ticker: BGLC
Reported as of: 13 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 17:18:36 UTC
Prior SEC filing: 31 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Muhammad Azrul Bin Abdul Hamid

Key filing fact

Muhammad Azrul bin Abdul Hamid filed Form 4 for BioNexus Gene Lab Corp (BGLC) on 14 Aug 2026.

Key facts

This page summarizes Muhammad Azrul bin Abdul Hamid's Form 4 filing for BioNexus Gene Lab Corp (BGLC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Aug 2026, 17:18.

Change

Previous filing in this sequence was filed on 31 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002141872 Primary reporting owner

Bin Abdul Hamid Muhammad Azrul

Relationship: Director
Address: NO 16 LORONG TABAN 2, LUCKY GARDEN BANGSAR, BANGSAR, MALAYSIA
Signature: /s/ Muhammad Azrul Bin Abdul Hamid
Signature date: 14 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BGLC transaction

Common Shares

Award

Transaction value
Shares: +32,258
Change %
Price
Shares after: 32,258
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).